Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by StockNews.com

Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Accelerate Diagnostics Stock Performance

Shares of AXDX stock remained flat at $1.64 during trading hours on Monday. The stock had a trading volume of 67,064 shares, compared to its average volume of 81,425. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $5.23. The stock has a market cap of $41.07 million, a PE ratio of -0.57 and a beta of 0.59. The firm has a 50-day moving average price of $1.79 and a two-hundred day moving average price of $1.51.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.